# Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy

> **NCT06825845** · — · NOT_YET_RECRUITING · sponsor: **CARsgen Therapeutics Co., Ltd.** · enrollment: 1500 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Zevorcabtagene Autoleucel

## Key facts

- **NCT ID:** NCT06825845
- **Lead sponsor:** CARsgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2039-12-31
- **Final completion:** 2040-06-30
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06825845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06825845, "Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06825845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*